Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Do you avoid adding high energy photons (with associated neutrons) for younger breast cancer patients, out of concern for secondary malignancy risk?
Answer from: Radiation Oncologist at Community Practice
We used mixed, whenever appropriate, with optimization of dose distribution using field within field technique (no wedges).
Sign in or Register to read more
9244
Related Questions
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
Would you forgo lumpectomy cavity boost for grade 1 papillary carcinoma with associated grade 1 DCIS that has been resected with good margins?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Is re-excision of residual disease ever itself an indication for PMRT?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
What are your top takeaways in Breast Cancer from ASCO 2025?
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?